Evidence map›Paper›PMID 39802397›Full record

ArticleThe journal of allergy and clinical immunology. Global2025

Stability of diluted chlorhexidine for skin testing in drug allergy evaluations.

Divya Shah, Gabriel Cojuc-Konigsberg, Stacy D Brown, Sergio E Chiarella, Gerald W Volcheck, Hirohito Kita, Lene H Garvey, Alexei Gonzalez-Estrada

Abstract read
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Hidden in plain sight: Chlorhexidine as the culprit in recurrent perioperative anaphylaxis.The journal of allergy and clinical immunology. Global · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Divya ShahDepartment of Internal Medicine, University of Arizona College of Medicine, Phoenix, Ariz.
Gabriel Cojuc-KonigsbergMedical School, Faculty of Health Sciences, Universidad Anahuac, Mexico City, Mexico.
Stacy D BrownDepartment of Pharmaceutical Sciences, East Tennessee State University, Johnson City, Tenn.
Sergio E ChiarellaDivision of Allergic Diseases, Mayo Clinic, Rochester, Minn.
Gerald W VolcheckDivision of Allergic Diseases, Mayo Clinic, Rochester, Minn.
Hirohito KitaDivision of Allergy, Asthma and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz.
Lene H GarveyDanish Anaesthesia Allergy Centre, Allergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
Alexei Gonzalez-EstradaDivision of Allergy, Asthma and Clinical Immunology, Mayo Clinic, Scottsdale, Ariz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chlorhexidine gluconate (CHX), a common cause of perioperative anaphylaxis, is frequently used for skin testing in allergy evaluations. Although CHX's maximal nonirritating concentrations are known, the stability of its dilutions for skin testing remains unexplored, particularly when sterile water for injection (SWFI) or normal saline (NS) are used as diluents. Objective: Our aim was to evaluate the stability and precipitation of CHX when diluted with SWFI or NS for drug allergy skin testing. Methods: CHX dilutions (5-0.002 mg/mL) were prepared using SWFI and NS. HPLC and UV-visible spectrophotometry were used to assess stability and precipitation over 48 hours. Turbidity was measured at various time points to monitor precipitation. Results: HPLC analysis showed no significant differences in peak heights between CHX-SWFI and CHX-NS dilutions. However, visible precipitation and increased turbidity (>100 NTU) were observed in CHX-NS at higher concentrations (5 mg/mL) after 60 minutes. No precipitation occurred in CHX-SWFI at any concentration for 48 hours. Conclusion: For CHX skin testing, SWFI is the preferred diluent at concentrations higher than 0.02 mg/mL to avoid precipitation. Using NS for the final dilution from 0.02 to 0.002 mg/mL is feasible and reduces injection pain. Except for CHX-NS at 5 mg/mL, reagents can be prepared up to 24 hours before testing.

Indexed as

Chlorhexidine/adverse effectsdrug hypersensitivity/diagnosisdrug stabilityhumansskin tests

Identifiers

PMID39802397
PMCPMC11719288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.